Celltrion Healthcare

Herzuma

Herzuma

Herzuma® is an oncology mAb biosimilar developed by Celltrion and approved by FDA and EMA.

• Product Name : Herzuma®
• INN : Trastuzumab
• Indications : HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), Metastatic Gastric Cancer(MGC)
• Protein Type : Monoclonal antibody (mAb)
• Mechanism of Action : It binds to the HER2 receptor overexpressed on the surface of breast cancer cells, as an antibody, to prevent the proliferation and rapid growth of breast cancer cells.
• Drug Approval Status : Korea, USA, Europe, Japan, Brazil, etc.